Problems with Chronic Opioid Therapy and the Need for a Multidisciplinary Approach

Chronic Pain Management: Guidelines for Multidisciplinary Program Development

Volumn , Issue , 2007, Pages 49-64

  Ballantyne, Jane C ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77956060981     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.3109/9781420045130-4     Document Type: Chapter

References (94)

1. Kreek MJ, Nielsen DA, Butelman ER, et al. Genetic influences on impulsivity, risk taking, stress responsivity and vulnerability to drug abuse and addiction. Nat Neurosci 2005; 8(11):1450-1457.
2. Hyman S. Dispelling the myths about addiction. Institute of Medicine. Washington, DC: National Academy of Sciences Press 1997:44-46.
3. Kreek MJ. Drug addictions: molecular and cellular endpoints. Ann NY Acad Sci 2001; 937:27-49.
4. Cami J, Farre M. Drug addiction. N Engl J Med 2003; 349:975-986.
5. Hyman S, Malenka R. Addiction and the brain: the neurobiology of compulsion and its persistence. Nat Rev Neurosci 2001; 2:695-703.
6. Hyman SE, Malenka RC, Nestler EJ. Neural mechanisms of addiction: the role of reward-related learning and memory. Annu Rev Neurosci 2006; 29:565-598.
7. Koob G, Le Moal M. Drug addiction, dysregulation of reward, and allostasis. Neuropharm 2001; 24:97-129.
8. Koob G, Le Moal M. Drug abuse: hedonic homeostatic dysregulation. Science 1997; 278:52-58.
9. Koob G, Maldonado R, Stinus L. Neural substrates of opiate withdrawal. Trends Neurosci 1992; 15(5):186-191.
10. Nestler EJ, Aghajanian GK. Molecular and cellular basis of addiction. Science 1997; 278(5335):58-63.
11. Nestler EJ. Historical review: molecular and cellular mechanisms of opiate and cocaine addiction. Trends Pharmacol Sci 2004; 25(4):210-218.
12. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn (DSM-IV). Washington, DC: American Psychiatric Association; 1994.
13. Savage S, Covington E, Ehit H, et al. Definitions related to the use of opioids for the treatment of pain. A consensus document from the American Academy of Pain Medicine, the American Pain Society and the American Society of Addiction Medicine, 2001.
14. Porter J, Jick H. Addiction rare in patients treated with narcotics (Letter). N Engl J Med 1980; 302(2):123.
15. Portenoy RK, Foley KM. Chronic use of opioid analgesics in non-malignant pain:report of 38 cases. Pain 1986; 25:171-186.
16. Office of Applied Studies. National Survey on Drug Use and Health. Substance Abuse and Mental Services Administration (SAMHSA), 2004.
17. Fishbain D, Rosomoff H, Rosomoff R. Drug abuse, dependence and addiction in chronic pain patients. Clin J Pain 1992; 8:77-85.
18. Ballantyne J, Mao J. Opioid therapy for chronic pain. N Engl J Med 2003; 349:1943-1953.
19. Kalso E, Edwards J, Moore R, et al. Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain 2004; 112:372-380.
20. Furlan AD, Sandoval JA, Mailis-Gagnon A, et al. Opioid for chronic non cancer pain:A meta-analysis of effectiveness and side effects. Can Med Assoc J 2006; 174(11):589-594.
21. Watson CPN, Babul N. Efficacy of oxycodone in neuropathic pain. A randomized trial in postherpetic neuralgia. Neurology 1998; 50:1837-1841.
22. Huse E, Larbig W, Flor H, et al. The effect of opioids on phantom limb pain and cortical reorganization. Pain 2001; 90:47-55.
23. Harke H, Gretenkort P, Ladleif HU, et al. The response of neuropathic pain and pain in complex regional pain syndrome I to carbamazepine and sustained-release morphine in patients pretreated with spinal cord stimulation: a double-blinded randomized study. Anesth Analg 2001; 92:488-495.
24. Raja SN, Haythornthwaite JA, Pappagallo M, et al. A placebo-controlled trial comparing the analgesic and cognitive effects of opioids and tricyclic antidepressants in postherpetic neuralgia. Neurology 2002; 59:1015-1021.
25. Gimbel JS, Richards P, Portenoy RK. Controlled-release oxycodone for pain in diabetic neuropathy: a randomized controlled trial [see comment]. Neurology 2003; 60(6):927-934.
26. Watson CPN, Moulin D, Watt-Watson J, et al. Controlled-release oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathy. Pain 2003; 105:71-78.
27. Morley JS, Bridson J, Nash TP, et al. Low-dose methadone has an analgesic effect in neuropathic pain: a double-blind randomized controlled crossover trial. Palliat Med 2003; 17(7):576-587.
28. Rowbotham MD, Twilling L, Davies PS, et al. Oral opioid therapy for chronic peripheral and central neuropathic pain. N Engl J Med 2003; 348:1223-1232.
29. Kalso E. Opioids for persistent non-cancer pain. BMJ 2005; 330:156-157.
30. Moore RA, McQuay HJ. Prevalence of opioid adverse events in chronic nonmalignant pain: systematic review of randomised trials of oral opioids. Arthritis Res Ther 2005; 7(5):R1046-1051.
31. Eriksen J, Sjogren P, Bruera E, et al. Critical issues on opioids in chronic non-cancer pain. An epidemiological study. Pain 2006; 125:172-179.
32. Portenoy RK. Opioid therapy for chronic nonmalignant pain: a review of the critical issues. J Pain Symptom Manage 1996; 11:203-217.
33. Katz N. Methodological issues in clinical trials of opioids for chronic pain. Neurology 2005; 65(12, Suppl 4):S32-S49.
34. Ballantyne JC. Opioids for chronic pain: taking stock. Pain 2006; 125:3-4.
35. Mao J. Opioid induced abnormal pain sensitivity: implications in clinical opioid therapy. Pain 2002; 100:213-217.
36. Mercadante S. Opioid rotation for cancer pain: rationale and clinical aspects. Cancer 1999; 86:1856-1866.
37. Schofferman J. Long-term use of opioid analgesics for the treatment of chronic pain of nonmalignant origin. J Pain Symptom Manage 1993; 8:279-288.
38. Harden RN. Chronic opioid therapy: another reappraisal. Aust Prosthodont Soc Bull 2002; 12(1). Available at http://www.ampainsoc.org/pub/bulletin/jan02/poli1.htm. Accessed on 5/11/07.
39. Mao J, Price D, Mayer D. Thermal hyperalgesia in association with the development of morphine tolerance in rats: roles of excitatory amino acid receptors and protein kinase C. J Neurosci 1994; 14:2301-2312.
40. Mao J, Price DD, Mayer DJ. Mechanisms of hyperalgesia and opiate tolerance: a current view of their possible interactions. Pain 1995; 62:259-274.
41. Chu LF, Clark D, Angst M. Opioid tolerance and hyperalgesia in chronic pain patients after one month of oral morphine therapy: a preliminary prospective study. J Pain 2006; 7(1):43-48.
42. Angst MS, Clark JD. Opioid-induced hyperalgesia: a qualitative systematic review. Anesthesiology 2006; 104(3):570-587.
43. Wilder-Smith O, Arendt-Nielsen L. Postoperative hyperalgesia: its clinical importance and relevance. Anesthesiology 2006; 104(3):601-607.
44. Devulder J, Richarz U, Nataraja SH. Impact of long-term use of opioids on quality of life in patients with chronic, non-malignant pain. Curr Med Res Opin 2005; 21(10):1555-1568.
45. Becker N, Sjogren P, Bech P, et al. Treatment outcome of chronic non-malignant pain patients managed in a danish multidisciplinary pain centre compared to general practice: a randomised controlled trial. Pain 2000; 84(2-3):203-211.
46. Bruera E, Macmillan K, Hanson J, et al. The cognitive effects of the administration of narcotic analgesic in patients with cancer pain. Pain 1989; 39:13-16.
47. Vainio A, Ollila J, Matikainen E, et al. Driving ability in cancer patients receiving long-term morphine analgesia. Lancet 1995; 346:667-670.
48. Galski T, Willimas B, Ehle HT. Effects of opioids on driving ability. J Pain Symptom Manage 2000; 19:200-208.
49. Haythornthwaite JA, Menefee LA, Quatrano-Piacentini AL, et al. Outcome of chronic opioid therapy for non-cancer pain. J Pain Symptom Manage 1998; 15:185-194.
50. Tassain V, Attal N, Fletcher D, et al. Long term effects of oral sustained release morphine on neuropsychological performance in patients with chronic non-cancer pain. Pain 2003; 104(1-2):389-400.
51. Kamboj SK, Tookman A, Jones L, et al. The effects of immediate-release morphine on cognitive functioning in patients receiving chronic opioid therapy in palliative care. Pain 2005; 117(3):388-395.
52. Sjogren P, Christrup LL, Petersen MA, et al. Neuropsychological assessment of chronic non-malignant pain patients treated in a multidisciplinary pain centre. Eur J Pain 2005; 9(4):453-462.
53. Mendelson JH, Mendelson JE, Patch VD. Plasma testosterone levels in heroin addiction and during methadone maintenance. J Pharmacol Exp Ther 1975; 192:211-217.
54. Daniell HW. The association of endogenous hormone levels and exogenously administered opiates in males. Am J Pain Manage 2001; 11(1):8-10.
55. Daniell HW. Hypogonadism in men consuming sustained-action oral opioids. J Pain 2002; 3(5):377-384.
56. Finch PM, Roberts LJ, Price L, et al. Hypogonadism in patients treated with intrathecal morphine. Clin J Pain 2000; 3:251-254.
57. DHHS, SAMHSA: National Household Survey on Drug Abuse Main Findings. Series H-11, 1998.
58. AAPM Council on Ethics. American Academy of Pain Medicine. Ethics Charter. Available at www.painmed.org/productpub/pdfs/EthicsCharter.pdf. 2005.
59. Carr DB, Goudas LC. Acute pain. Lancet 1999; 353(9169):2051-2058.
60. Kehlet H, Dahl JB. Anaesthesia, surgery, and challenges in postoperative recovery. Lancet 2003; 362(9399):1921-1928.
61. Brennan TJ, Kehlet H. Preventive analgesia to reduce wound hyperalgesia and persistent postsurgical pain. Not an easy path. Anesthesiolgy 2005; 103:681-683.
62. Dubois MY. The birth of an ethics charter for pain medicine. Pain Med 2005; 6(3):201-202.
63. Joranson DE, Gilson AM, Dahl JL, et al. Pain medicine, controlled substances, and state medical board policy: a decade of change. J Pain Symptom Manage 2002; 23:138-147.
64. Joranson D, Gilson A. State intractable pain policy: current status. Aust Prosthodont Soc Bull 1997; 7(2):7-9.
65. Drug Enforcement Administration. Physician’s Manual: An Informational Outline of the Controlled Substances Act of 1970. Washington DC: U.S. Department of Justice, 1990.
66. Opinions on Practice Matters, sec 8.081:222,223. Code of Medical Ethics, Current Opinions With Annotations, 2004-2005 Ed. Chicago: American Medical Association; 2004.
67. Fields HL. Ethical standards in pain management and research. In: Fields HL, ed. Core Curriculum for Professional Education in Pain. Seattle: IASP Press; 1995:117-123.
68. Dubois MY. Why an “ethics” forum in Pain Medicine. Pain Med 2000; 1(2):105-106.
69. Sullivan M. Ethical principles in pain management. Pain Med 2001; 2:106-111.
70. Chabal C, Erjavec M, Jacobson L, et al. Prescription opiate abuse in chronic pain patinets: clinical criteria, incidence and predictors. Clin J Pain 1997; 13:150-155.
71. Compton P, Darakjian J, Miotto K. Screening for addiction in patients with chronic pain with “problematic” substance use: evaluation of a pilot assessment tool. J Pain Symptom Manage 1998; 16:355-363.
72. Passik SD, Kirsh KL, Whitcomb L, et al. A new tool to assess and document pain outcomes in chronic pain patients receiving opioid therapy. Clin Ther 2004; 26(4):552-561.
73. Adams L, Gatchel R, Robinson RC, et al. Development of a self-report screening instrument for assessing potential opioid medication misuse in chronic pain patients. J Pain Sympt Manage 2004; 27(5):440-459.
74. Butler S, Budman S, Fernandez K, et al. Validation of a screener and opioid assessment measure for patients with chronic pain. Pain 2004; 112:65-75.
75. Webster L, Webster R. Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the Opioid Risk Tool. Pain Med 2005; 6(6):432-442.
76. Friedman R, Li V, Mehrotra D. Treating pain patients at risk: evaluation of a screening tool in opioid-treated pain patients with and without addiction. Pain Med 2003; 4(2):182-185.
77. Collett BJ. Chronic opioid therapy for non-cancer pain. Br J Anaesth 2001; 87:133-144.
78. West J, Aronoff G, Dahl J, et al. Model guidelines for the use of controlled substances for the treatment of pain. A policy document of the Federation of State Medical Boards of the United States, Inc. Federation of State Medical Boards of the United States, Inc, Euless, TX; 1998.
79. Haddox JD, Joranson D, Angarola RT, et al. The use of opioids for the treatment of chronic pain. A consensus statement from the American Academy of Pain Medicine and the American Pain Society. American Academy of Pain Medicine and American Pain Society, 1997.
80. Evidence-based recommendations for medical management of chronic nonmalignant pain. Reference Guide for Clinicians. Ontario: The College of Physicians and Surgeons of Ontario; 2000.
81. Jovey R, Ennis J, Gardner-Nix J, et al. Use of opioid analgesics for the treatment of chronic noncancer pain-a consensus statement and guidelines from the Canadian Pain Society, 2002. Pain Res Manage 2003; 8(Suppl A):3A-28A.
82. VA/DoD clinical practice guideline for the management of opioid therapy for chronic pain. Available at www.Oqp.Med.Va.Gov?Cpg/Cpg.Htm. 2006. Accessed on 10/24/2006.
83. Atluri S, Boswell MV, Hansen HC, et al. Guidelines for the use of controlled substances in the management of chronic pain. Pain Physician 2003; 6(3):233-257.
84. Kalso E, Allan L, Dellemijn P, et al. Recommendations for using opioids in chronic non-cancer pain. Eur J Pain 2003; 7(5):381-386.
85. Recommendations for the appropriate use of opioids for persistent non-cancer pain. A Consensus Statement Prepared on Behalf of the British Pain Society, the Royal College of Anaesthetists, the Royal College of General Practitioners, and the Royal College of Psychiatrists. London: The British Pain Society; 2005.
86. Red Book. Drug Topics. Top 200 Brand-Name Drugs by Prescription. Montvale, NJ:Medical Economics; March 6, 2002.
87. Turk DC. Clinical effectiveness and cost-effectiveness of treatments for patients with chronic pain. Clin J Pain 2002; 18:355-365.
88. Flor H, Fydrich T, Turk DC. Efficacy of multidisciplinary pain treatment centers: A meta-analytic review. Pain 1992; 49:221-230.
89. Patrick LE, Altmaier EM, Found EM. Long-term outcomes in multidisciplinary treatment of chronic low back pain: results of a 13-year follow-up. Spine 2004; 29:850-855.
90. Guzman J, Esmail R, Karjalainen K, et al. Multidisciplinary rehabilitation for chronic low back pain: systematic review. BMJ 2001; 322:1511-1516.
91. Lin EH, Katon W, Von Korff M, et al. Effect of improving depression care on pain and functional outcomes among older adults with arthritis: a randomized controlled trial. JAMA 2003; 290:2428-2429.
92. Ballantyne J. Pharmacology and practice of opioid drugs for visceral pain. In: Pasricha P, Willis W, Gebhart G, eds. Chronic Abdominal and Visceral Pain: Theory and Practice; 2006.
93. Fishman SM, Mao J. Opioid therapy in chronic nonmalignant pain. In: Ballantyne JC, ed. The Massachusetts General Hospital Handbook of Pain Management, 3rd edn. Philadelphia, PA: LippincottWilliams &Wilkins; 2005.
94. Ballantyne J. Opioid therapy: is it appropriate in patients with noncancer pain? An evidence-based look at the issue. ASA Refresher Courses in Anesthesiology, vol. 34, Chapter 3, American Society of Anesthesiologists, Philadelphia, PA: Lippincott Williams &Wilkins; 2006.